Home > Dermatology > AAD 2019 > Late-Breakers > New standardised cantharidin product against molluscum contagiosum efficacious in two phase 3 trials

New standardised cantharidin product against molluscum contagiosum efficacious in two phase 3 trials

Presented By
Prof. Lawrence Eichenfield, University of California, San Diego School of Medicine and Rady´s Children´s Hospital, USA
Conference
AAD 2019
Trial
CAMP

The two trials CAMP-1 and CAMP-2 demonstrated a high efficacy of VP-102, a topical therapy containing a solution of 0.7% cantharidin in a novel, single-use applicator to treat and eradicate molluscum contagiosum (MC) [1].

MC is a common and highly contagious skin disease. Since it is self-limited in healthy individuals, treatment is not always necessary. Nonetheless, issues such as lesion visibility, underlying atopic disease, and the desire to prevent transmission may prompt therapy. "Sometimes the infection persists for over 2 years, so there is a medical need for an approved treatment for this disease," said Prof. Lawrence Eichenfield (University of California, San Diego School of Medicine and Rady´s Children´s Hospital, USA).

Current treatment consists of cryosurgery curettage followed by cantharidin treatment. VP-102 is a novel standardised cantharidin product with a special applicator that allows precise dosing of MC lesions. It contains a vis...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on